La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Yantai Zhenghai Biotechnology Croissance future
Future contrôle des critères 5/6
Yantai Zhenghai Biotechnology is forecast to grow earnings and revenue by 22.1% and 19.6% per annum respectively. EPS is expected to grow by 22.2% per annum. Return on equity is forecast to be 23.8% in 3 years.
Informations clés
22.1%
Taux de croissance des bénéfices
22.2%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 34.3% |
Taux de croissance des recettes | 19.6% |
Rendement futur des capitaux propres | 23.8% |
Couverture par les analystes | Low |
Dernière mise à jour | 09 Aug 2024 |
Mises à jour récentes de la croissance future
Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 636 | 296 | N/A | 301 | 1 |
12/31/2025 | 547 | 253 | N/A | 264 | 2 |
12/31/2024 | 453 | 208 | N/A | 224 | 2 |
6/30/2024 | 387 | 167 | 143 | 174 | N/A |
3/31/2024 | 394 | 178 | 135 | 165 | N/A |
12/31/2023 | 414 | 191 | 149 | 180 | N/A |
9/30/2023 | 414 | 178 | 135 | 166 | N/A |
6/30/2023 | 426 | 191 | 122 | 168 | N/A |
3/31/2023 | 425 | 184 | 128 | 175 | N/A |
1/1/2023 | 433 | 185 | 132 | 188 | N/A |
9/30/2022 | 440 | 197 | 139 | 179 | N/A |
6/30/2022 | 431 | 192 | 179 | 192 | N/A |
3/31/2022 | 416 | 180 | 190 | 193 | N/A |
12/31/2021 | 400 | 169 | 156 | 166 | N/A |
9/30/2021 | 378 | 149 | 109 | 171 | N/A |
6/30/2021 | 360 | 144 | 69 | 150 | N/A |
3/31/2021 | 351 | 143 | 38 | 143 | N/A |
12/31/2020 | 293 | 118 | 15 | 118 | N/A |
9/30/2020 | 295 | 123 | 35 | 115 | N/A |
6/30/2020 | 282 | 111 | 50 | 115 | N/A |
3/31/2020 | 263 | 100 | 28 | 91 | N/A |
12/31/2019 | 280 | 107 | 41 | 103 | N/A |
9/30/2019 | 251 | 100 | 44 | 91 | N/A |
6/30/2019 | 243 | 97 | 46 | 83 | N/A |
3/31/2019 | 230 | 91 | 61 | 84 | N/A |
12/31/2018 | 216 | 86 | 71 | 77 | N/A |
9/30/2018 | 216 | 88 | 71 | 77 | N/A |
6/30/2018 | 204 | 81 | 66 | 77 | N/A |
3/31/2018 | 193 | 76 | N/A | 76 | N/A |
12/31/2017 | 183 | 62 | N/A | 65 | N/A |
9/30/2017 | 176 | 54 | N/A | 68 | N/A |
6/30/2017 | 164 | 47 | N/A | 60 | N/A |
3/31/2017 | 159 | 46 | N/A | 56 | N/A |
12/31/2016 | 151 | 45 | N/A | 49 | N/A |
6/30/2016 | 138 | 43 | N/A | 45 | N/A |
3/31/2016 | 126 | 41 | N/A | 41 | N/A |
12/31/2015 | 128 | 42 | N/A | 46 | N/A |
12/31/2014 | 105 | 34 | N/A | 31 | N/A |
12/31/2013 | 77 | 16 | N/A | 34 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 300653's forecast earnings growth (22.1% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 300653's earnings (22.1% per year) are forecast to grow faster than the CN market (21.9% per year).
Croissance élevée des bénéfices: 300653's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 300653's revenue (19.6% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 300653's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 300653's Return on Equity is forecast to be high in 3 years time (23.8%)